All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma

Torahiko Nakashima, Shi Yong Sun, Reuben Lotan, Toshiyoshi Fujiwara, Ryuji Yasumatsu, Sohtaro Komiyama, Gary L. Clayman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P <.05). p53 expression significantly increased more after the combined treatment than after either treatment alone, at both the transcription and protein levels. In addition, increased expression of p21 and BAX, which are downstream gene products of p53, was observed in the combination. ATRA also enhanced the expression of green fluorescent protein (GFP) transduced by an adenovirus-cytomegalovirus (CMV)-GFP vector suggesting ATRA enhances adenovirus-CMV-promoted vectors through transcription. Conclusions: Our results indicate that ATRA enhances AdCMVp53 expression through transcriptional mechanisms and can synergistically induce apoptosis in HNSCC cells. ATRA has a potential to enhance the effect of adenovirus-mediated p53 gene therapy for HNSCC.

Original languageEnglish
Pages (from-to)1459-1464
Number of pages6
JournalLaryngoscope
Volume111
Issue number8
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

p53 Genes
Tretinoin
Adenoviridae
Genetic Therapy
Cytomegalovirus
Therapeutics
Apoptosis
Phase III Clinical Trials
Retinoids
Growth
Green Fluorescent Proteins
Carcinoma, squamous cell of head and neck
Cell Cycle
Cell Proliferation
Viruses
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. / Nakashima, Torahiko; Sun, Shi Yong; Lotan, Reuben; Fujiwara, Toshiyoshi; Yasumatsu, Ryuji; Komiyama, Sohtaro; Clayman, Gary L.

In: Laryngoscope, Vol. 111, No. 8, 01.01.2001, p. 1459-1464.

Research output: Contribution to journalArticle

Nakashima, Torahiko ; Sun, Shi Yong ; Lotan, Reuben ; Fujiwara, Toshiyoshi ; Yasumatsu, Ryuji ; Komiyama, Sohtaro ; Clayman, Gary L. / All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. In: Laryngoscope. 2001 ; Vol. 111, No. 8. pp. 1459-1464.
@article{396ee1341953487baf938a49ff49489f,
title = "All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma",
abstract = "Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P <.05). p53 expression significantly increased more after the combined treatment than after either treatment alone, at both the transcription and protein levels. In addition, increased expression of p21 and BAX, which are downstream gene products of p53, was observed in the combination. ATRA also enhanced the expression of green fluorescent protein (GFP) transduced by an adenovirus-cytomegalovirus (CMV)-GFP vector suggesting ATRA enhances adenovirus-CMV-promoted vectors through transcription. Conclusions: Our results indicate that ATRA enhances AdCMVp53 expression through transcriptional mechanisms and can synergistically induce apoptosis in HNSCC cells. ATRA has a potential to enhance the effect of adenovirus-mediated p53 gene therapy for HNSCC.",
author = "Torahiko Nakashima and Sun, {Shi Yong} and Reuben Lotan and Toshiyoshi Fujiwara and Ryuji Yasumatsu and Sohtaro Komiyama and Clayman, {Gary L.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1097/00005537-200108000-00024",
language = "English",
volume = "111",
pages = "1459--1464",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma

AU - Nakashima, Torahiko

AU - Sun, Shi Yong

AU - Lotan, Reuben

AU - Fujiwara, Toshiyoshi

AU - Yasumatsu, Ryuji

AU - Komiyama, Sohtaro

AU - Clayman, Gary L.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P <.05). p53 expression significantly increased more after the combined treatment than after either treatment alone, at both the transcription and protein levels. In addition, increased expression of p21 and BAX, which are downstream gene products of p53, was observed in the combination. ATRA also enhanced the expression of green fluorescent protein (GFP) transduced by an adenovirus-cytomegalovirus (CMV)-GFP vector suggesting ATRA enhances adenovirus-CMV-promoted vectors through transcription. Conclusions: Our results indicate that ATRA enhances AdCMVp53 expression through transcriptional mechanisms and can synergistically induce apoptosis in HNSCC cells. ATRA has a potential to enhance the effect of adenovirus-mediated p53 gene therapy for HNSCC.

AB - Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P <.05). p53 expression significantly increased more after the combined treatment than after either treatment alone, at both the transcription and protein levels. In addition, increased expression of p21 and BAX, which are downstream gene products of p53, was observed in the combination. ATRA also enhanced the expression of green fluorescent protein (GFP) transduced by an adenovirus-cytomegalovirus (CMV)-GFP vector suggesting ATRA enhances adenovirus-CMV-promoted vectors through transcription. Conclusions: Our results indicate that ATRA enhances AdCMVp53 expression through transcriptional mechanisms and can synergistically induce apoptosis in HNSCC cells. ATRA has a potential to enhance the effect of adenovirus-mediated p53 gene therapy for HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=0034903213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034903213&partnerID=8YFLogxK

U2 - 10.1097/00005537-200108000-00024

DO - 10.1097/00005537-200108000-00024

M3 - Article

VL - 111

SP - 1459

EP - 1464

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 8

ER -